Actemra (tocilizumab subcutaneous injection) — Medica

Initial criteria

• age > 2 years
• patient has tried one other systemic therapy (e.g., methotrexate, sulfasalazine, leflunomide, NSAID, or one biologic other than tocilizumab) OR will be starting concurrently with methotrexate, sulfasalazine, or leflunomide OR has an absolute contraindication to methotrexate, sulfasalazine, or leflunomide OR has aggressive disease as determined by prescriber
• prescribed by or in consultation with a rheumatologist

Approval duration

6 months